company background image
SANA

Sana Biotechnology NasdaqGS:SANA Stock Report

Last Price

US$4.48

Market Cap

US$850.8m

7D

-8.9%

1Y

-39.2%

Updated

09 Feb, 2023

Data

Company Financials +

Sana Biotechnology, Inc.

NasdaqGS:SANA Stock Report

Mkt Cap: US$850.8m

SANA Stock Overview

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.

SANA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Sana Biotechnology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sana Biotechnology
Historical stock prices
Current Share PriceUS$4.48
52 Week HighUS$9.60
52 Week LowUS$3.15
Beta0.60
1 Month Change14.29%
3 Month Change-25.58%
1 Year Change-39.21%
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.24%

Recent News & Updates

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Recent updates

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology: Exciting Preclinical Science

Feb 12

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Oct 13
Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Sana Biotechnology: Hypoimmune Cell Therapies

Jul 01

Sana Biotechnology reports Q1 results

May 05

Shareholder Returns

SANAUS BiotechsUS Market
7D-8.9%-1.8%-1.8%
1Y-39.2%1.9%-10.9%

Return vs Industry: SANA underperformed the US Biotechs industry which returned 1.9% over the past year.

Return vs Market: SANA underperformed the US Market which returned -10.9% over the past year.

Price Volatility

Is SANA's price volatile compared to industry and market?
SANA volatility
SANA Average Weekly Movement13.2%
Biotechs Industry Average Movement11.9%
Market Average Movement6.6%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: SANA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SANA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2018497Steve Harrhttps://www.sana.com

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency.

Sana Biotechnology, Inc. Fundamentals Summary

How do Sana Biotechnology's earnings and revenue compare to its market cap?
SANA fundamental statistics
Market CapUS$850.84m
Earnings (TTM)-US$299.76m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SANA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$299.76m
Earnings-US$299.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SANA perform over the long term?

See historical performance and comparison